Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab and tocotrienol in recurrent ovarian cancer
2019-000618-13Phase 2Terminated
- Sponsor
- Vejle Hospital
- Start
- May 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, single-arm trial of bevacizumab in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by Vejle Hospital. Primary endpoint: Progression-free survival after the first cycle of treatment. Started May 2019; status: terminated.
02
Drugs
bevacizumab
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on 2019-000618-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000618-13.